Blue Cross, Harvard Pilgrim and the other insured plans
Blue Cross Blue Shield of Massachusetts told members: "We've made the decision to end coverage for GLP-1 medications, except for type 2 diabetes," starting at plan renewals on or after January 1, 2026, and "If your company has fewer than 100 employees or you're a direct-pay member, you're not eligible to continue coverage" (Blue Cross Blue Shield of Massachusetts). Harvard Pilgrim's commercial plans and Tufts Health Direct exclude weight-loss drugs for weight loss and for "alternative indications," including heart conditions, with "no grandfathering of prior authorizations" (Point32Health). Mass General Brigham Health Plan stopped on January 1, 2026 for individual and small-employer members and at the 2026 renewal for large groups; employers with 50 or more enrolled subscribers may add it back (Mass General Brigham Health Plan). Health New England lets groups with 100 or more subscribers buy a rider (Health New England), and Fallon Health ended every weight-loss authorization on December 31, 2025 (Fallon Health). WellSense's Clarity plans stopped covering "drugs prescribed primarily for the treatment of weight loss" on January 1, 2026 (WellSense, November 21, 2025).
A job plan that pays its own claims follows federal law and your employer's choice, not these notices. CVS Caremark put Zepbound® back on its lists on October 1, 2026 for plan sponsors that elect coverage (CVS Health), so ask your HR office which kind of plan you have.
MassHealth
Since July 3, 2026, MassHealth no longer covers Wegovy®, Zepbound®, Saxenda® and other weight-loss drugs "when used only for the treatment of obesity or overweight," in every MassHealth plan. It still covers them with a new prior authorization for a BMI over 27 with established heart disease, a BMI over 30 with moderate to severe sleep apnea, MASH, and members under 21 when medically necessary. Wegovy® is now the sole preferred drug, and continuing on Zepbound® requires a trial of Wegovy® (MassHealth Pharmacy Facts 276, May 13, 2026). The change was expected to affect at least 22,000 members and save about $15 million a year (Boston.com, June 27, 2026). GLP-1s for type 2 diabetes are unchanged.
The GIC: state and municipal employees
The GIC's pharmacy benefit hasn't paid for GLP-1s for weight loss alone since July 1, 2026; some 22,000 members were taking them, at a cost of $46 million (WBUR, February 26, 2026). With a prior authorization through CVS Caremark it still covers MASH with moderate to advanced (F2 to F3) fibrosis, heart-risk reduction in established heart disease with a BMI of 27 or more, and moderate to severe sleep apnea with a BMI of 30 or more (GIC, June 2026 update). Retirees on the GIC's Medicare plans keep coverage for obesity through December 31, 2026 (Mass Retirees).
Medicare and the GLP-1 Bridge
1,519,172 Massachusetts residents had Medicare in July 2026, 1,269,030 of them with drug coverage (CMS, Medicare monthly enrollment). Through the federal GLP-1 Bridge, Part D members who meet its BMI and health criteria pay $50 a fill for Wegovy®, the Zepbound® KwikPen® or Foundayo™ from July 1, 2026 to December 31, 2027 (Medicare.gov; CMS). SHINE gives free Medicare counseling at 1-800-243-4636 (SHIP locator, Massachusetts).
TRICARE and the VA
TRICARE may cover prescription weight-loss drugs with prior authorization for Prime and Select members with a network prescriber, but not for TRICARE For Life (TRICARE). The VA prescribes Zepbound® for weight under its own criteria, including a lifestyle program (VA criteria), through VA Boston, Bedford, Central Western Massachusetts and, for southeastern Massachusetts, Providence.
If your plan says no
An exclusion can't be appealed: Blue Cross calls the change "a benefit exclusion that can't be appealed," and the state's external review won't take a service that is "explicitly excluded from coverage." A denial of a use your plan does cover, such as heart-risk reduction under MassHealth or the GIC, can go to the plan's appeal and then to an independent external review through the Health Policy Commission's Office of Patient Protection, for $25, waived for financial hardship (Office of Patient Protection).